Cardiff Oncology (NASDAQ:CRDF) Coverage Initiated at Jefferies Financial Group

Analysts at Jefferies Financial Group assumed coverage on shares of Cardiff Oncology (NASDAQ:CRDF - Get Free Report) in a research note issued on Tuesday, MarketBeat reports. The firm set a "hold" rating and a $3.50 price target on the stock. Jefferies Financial Group's price target would suggest a potential upside of 12.36% from the stock's previous close.

A number of other equities analysts also recently commented on CRDF. William Blair restated an "outperform" rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. HC Wainwright raised their price target on Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $9.88.

Cardiff Oncology Trading Down 1.4%

Cardiff Oncology stock traded down $0.05 during midday trading on Tuesday, hitting $3.12. The stock had a trading volume of 761,808 shares, compared to its average volume of 1,197,608. The business has a fifty day moving average price of $3.12 and a 200 day moving average price of $3.56. Cardiff Oncology has a 12 month low of $2.01 and a 12 month high of $5.64. The stock has a market cap of $207.24 million, a P/E ratio of -3.39 and a beta of 1.61.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). Cardiff Oncology had a negative return on equity of 76.45% and a negative net margin of 8,308.50%. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.09 million. On average, equities analysts anticipate that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

Institutional Trading of Cardiff Oncology

Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new position in shares of Cardiff Oncology in the fourth quarter worth $25,000. Ledgewood Wealth Advisors LLC bought a new stake in shares of Cardiff Oncology during the 1st quarter worth about $35,000. Belpointe Asset Management LLC bought a new stake in shares of Cardiff Oncology during the 1st quarter worth about $37,000. Castleview Partners LLC acquired a new stake in shares of Cardiff Oncology in the 1st quarter worth approximately $45,000. Finally, ProShare Advisors LLC bought a new position in shares of Cardiff Oncology in the fourth quarter valued at approximately $50,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.